FrancophonIA/ELRC3.0 huggingface dataset:
English: Children and adolescents Azacitidine Celgene is not recommended for use in children and adolescents below the age of 18.
Croatian: Ne preporučuje se primjena Azacitidina Celgene u djece i adolescenata mlađih od 18 godina.
English: Total dose based on BSA value of 1.8 m
Croatian: Ukupna doza prema vrijednosti PT-a od 1,8 m
English: Your doctor, pharmacist or nurse are responsible for storing Azacitidine Celgene.
Croatian: Vaš liječnik, ljekarnik ili medicinska sestra odgovorni su za čuvanje Azacitidina Celgene.
English: 2 D bar code carrying the unique identifier
Croatian: Sadrži 2D barkod s jedinstvenim identifikatorom.
English: Azacitidine Celgene should be reconstituted with water for injections.
Croatian: Azacitidin Celgene treba rekonstituirati vodom za injekcije.
English: Azacitidine Celgene is an anti-cancer agent which belongs to a group of medicines called ‘antimetabolites'.
Croatian: Azacitidin Celgene je lijek protiv raka i pripada skupini lijekova koji se zovu „antimetaboliti“.
English: Azacitidine treatment was also associated with a reduction in cytopenias, and their related symptoms.
Croatian: Liječenje azacitidinom također je bilo povezano sa smanjenjem citopenija i s njima povezanih simptoma.
English: Total dose (mg) = Dose (mg/m 2) x BSA (m
Croatian: Ukupna doza (mg) = doza (mg/m2) x PT (m
English: The Azacitidine Celgene suspension may be prepared immediately before use and the reconstituted suspension should be administered within 45 minutes.
Croatian: Suspenzija Azacitidina Celgene može se pripremiti neposredno prije primjene te rekonstituiranu suspenziju treba primijeniti unutar 45 minuta.
English: What Azacitidine Celgene is and what it is used for What you need to know before you use Azacitidine Celgene How to use Azacitidine Celgene Possible side effects
Croatian: Što je Azacitidin Celgene i za što se koristi Što morate znati prije nego počnete primjenjivati Azacitidin Celgene Kako primjenjivati Azacitidin Celgene Moguće nuspojave
English: Before giving you Azacitidine Celgene, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle.
Croatian: Prije primjene Azacitidina Celgene, liječnik će Vam dati drugi lijek za sprječavanje mučnine i povraćanja na početku svakoga ciklusa liječenja.
English: Haematological toxicity is defined as the lowest count reached in a given cycle (nadir) if platelets ≤ 50.0 x 10
Croatian: Hematološka toksičnost definirana je kao najniža vrijednost dosegnuta u određenom ciklusu ako su trombociti ≤ 50,0 x 10
English: This is because Azacitidine Celgene may affect the way some other medicines work.
Croatian: To je potrebno zbog toga što Azacitidin Celgene može utjecati na djelovanje drugih lijekova.
English: Other medicines and Azacitidine Celgene
Croatian: Drugi lijekovi i Azacitidin Celgene
English: Men should not father a child while receiving treatment with Azacitidine Celgene.
Croatian: Muškarci ne smiju začeti dijete tijekom liječenja Azacitidinom Celgene.
English: What you need to know before you use Azacitidine Celgene
Croatian: Što morate znati prije nego počnete primjenjivati Azacitidin Celgene
English: • Sore or runny nose or sinuses (sinusitis).
Croatian: • bolan nos ili curenje iz nosa ili sinusa (sinusitis)
English: Azacitidine Celgene treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents.
Croatian: Liječenje Azacitidinom Celgene treba započeti i nadzirati liječnik iskusan u primjeni kemoterapijskih lijekova.
English: A survival benefit was also demonstrated in patients that had not achieved a complete response for azacitidine compared to CCR.
Croatian: Korist za preživljenje također je bila dokazana u bolesnika koji nisu bili postigli potpuni odgovor na azacitidin u usporedbi s CCR-om.
English: The absolute bioavailability of azacitidine after subcutaneous relative to intravenous administration (single 75 mg/m doses) was approximately 89% based on area under the curve (AUC).
Croatian: Apsolutna bioraspoloživost azacitidina nakon supkutane primjene u odnosu na intravensku primjenu (jednokratnih doza od 75 mg/m2) bila je približno 89 % na osnovi površine ispod krivulje (AUC).
English: Also, some other medicines may affect the way Azacitidine Celgene works.
Croatian: Isto tako, drugi lijekovi mogu utjecati na djelovanje Azacitidina Celgene.
English: What Azacitidine Celgene looks like and contents of the pack Azacitidine Celgene is a white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine.
Croatian: Kako Azacitidin Celgene izgleda i sadržaj pakiranja Azacitidin Celgene je bijeli prašak za suspenziju za injekciju pohranjen u staklenoj bočici koja sadrži 100 mg azacitidina.
English: Azacitidine Celgene is a cytotoxic medicinal product and, as with other potentially toxic compounds, caution should be exercised when handling and preparing azacitidine suspensions.
Croatian: Azacitidin Celgene je citotoksični lijek te je, kao i s drugim potencijalno toksičnim tvarima, potreban oprez pri rukovanju i pripremi suspenzija azacitidina.
English: The one-year survival rates were 46.5% in patients receiving azacitidine versus 34.3% in patients receiving CCR.
Croatian: Stope jednogodišnjeg preživljenja iznosile su 46,5 % u bolesnika koji su primali azacitidin naspram 34,3 % u bolesnika koji su primali CCR.
English: Talk to your doctor, pharmacist or nurse before using Azacitidine Celgene:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego što Vam je primijenjen Azacitidin Celgene:
English: • acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
Croatian: • akutne mijeloične leukemije (AML) s 20-30 % blasta i displazijom više loza, prema klasifikaciji Svjetske zdravstvene organizacije (SZO),
English: Talk to your doctor or nurse if you have any questions about how Azacitidine Celgene works or why this medicine has been prescribed for you.
Croatian: Razgovarajte sa svojim liječnikom ili medicinskom sestrom ako imate pitanja o tome kako djeluje Azacitidin Celgene ili zašto
English: 1 vial - 100 mg
Croatian: 1 bočica - 100 mg
English: Azacitidine plus BSC (n=241) was compared to CCR.
Croatian: Azacitidin uz BSC (n = 241) bio je uspoređen s CCR-om.
English: Adult population with MDS, CMML and AML (20-30% marrow blasts) Adverse reactions considered to be possibly or probably related to the administration of azacitidine have occurred in 97 % of patients.
Croatian: Odrasla populacija s MDS-om, KMML-om i AML-om (20-30 % blasta u koštanoj srži) Nuspojave za koje se smatra da su možda ili vjerojatno povezane s primjenom azacitidina pojavile su se kod 97 % bolesnika.
English: The Cox PH model adjusted for pre-specified baseline prognostic factors defined a HR for azacitidine versus CCR of 0.80 (95% CI= 0.66, 0.99; p = 0.0355).
Croatian: Prema Coxovu modelu prilagođenom za prije određene početne prognostičke faktore, određen je omjer hazarda za azacitidin u usporedbi s CCR-om od 0,80 (95% CI = 0,66; 0,99; p = 0,0355).
English: Read the leaflet for the shelf life of the reconstituted medicine.
Croatian: Pročitajte uputu o lijeku za rok valjanosti rekonstituiranog lijeka.
English: Number of vials required
Croatian: Broj potrebnih bočica
English: What Azacitidine Celgene is and what it is used for
Croatian: Što je Azacitidin Celgene i za što se koristi
English: In addition, although the study was not powered to demonstrate a statistically significant difference when comparing azacitidine to the preselection CCR treatment groups, the survival of azacitidine treated patients was longer when compared to CCR treatment options BSC alone, low-dose cytarabine plus BSC and were similar when compared to standard intensive chemotherapy plus BSC.
Croatian: Uz to, iako ispitivanje nije imalo dovoljnu snagu da se dokaže statistički značajna razlika između skupine liječene azacitidinom i skupine liječene CCR-om prije selekcije, preživljenje bolesnika liječenih azacitidinom bilo je dulje u usporedbi s mogućnostima liječenja CCR-om samo BSC-om, niskom dozom citarabina uz BSC te je bilo slično kad se usporedilo sa standardnom intenzivnom kemoterapijom uz BSC.
English: The efficacy and safety of azacitidine was studied in an international, multicentre, controlled, openlabel, parallel group Phase 3 study in patients 65 years and older with newly diagnosed de novo or secondary AML with >30% bone marrow blasts according to the WHO classification, who were not eligible for HSCT.
Croatian: Djelotvornost i sigurnost azacitidina bila je ispitana u međunarodnom, multicentričnom, kontroliranom, otvorenom ispitivanju faze 3 na usporednim skupinama bolesnika u dobi od 65 i više godina s novodijagnosticiranom de novo ili sekundarnom AML s > 30 % blasta u koštanoj srži prema klasifikaciji SZO-a, koji nisu zadovoljavali kriterije za THMS.
English: Following intravenous and subcutaneous administration of C-azacitidine, 85 and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces.
Croatian: C-azacitidina, 85 i 50 % primijenjene radioaktivnosti nađeno je u urinu, dok je < 1 % nađeno u stolici.
English: The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m of body surface area, injected subcutaneously, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle).
Croatian: Preporučena početna doza za prvi ciklus liječenja za sve je bolesnike, bez obzira na početne hematološke laboratorijske vrijednosti, 75 mg/m površine tijela, a injicira se supkutano, jednom dnevno tijekom 7 dana, nakon čega slijedi stanka od 21 dana (28-dnevni ciklus liječenja).
English: Patients without reduced baseline blood counts (i.e. White Blood Cells (WBC) ≥ 3.0 x 10
Croatian: Bolesnici bez smanjenih početnih vrijednosti krvne slike (tj. bijele krvne stanice ≥ 3,0 x 10
English: 9/l and/or absolute neutrophil count (ANC) ≤ 1 x 10
Croatian: 9/L i/ili ako je apsolutni broj neutrofila (ABN) ≤ 1 x 10 9/L.
English: Azacitidine was administered at a subcutaneous dose of 75 mg/m daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle) for a median of 9 cycles (range = 1-39) and a mean of 10.2 cycles.
Croatian: Azacitidin se primjenjivao supkutano u dozi od 75 mg/m dnevno tijekom 7 dana, zatim je slijedilo razdoblje odmora od 21 dana (28-dnevni ciklus liječenja) za medijan od 9 ciklusa (raspon = 1-39) i prosjek od 10,2 ciklusa.
English: Adult population (MDS, CMML and AML [20-30% marrow blasts]) The efficacy and safety of azacitidine were studied in an international, multicenter, controlled, openlabel, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in adult patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.
Croatian: Odrasla populacija (MDS, KMML i AML [20-30 % blasta u koštanoj srži]) Djelotvornost i sigurnost azacitidina ispitivane su u međunarodnom, multicentričnom kontroliranom, otvorenom, randomiziranom, komparativnom ispitivanju faze 3 u paralelnim skupinama (AZA PH GL 2003 CL 001) u odraslih bolesnika sa: srednjim 2 i visokim rizikom MDS-a prema međunarodnom prognostičkom numeričkom sustavu rangiranja (IPSS), refraktornom anemijom sa suviškom blasta (RAEB), refraktornom anemijom sa suviškom blasta u transformaciji (RAEB-T) i modificiranom kroničnom mijelomonocitnom leukemijom (mKMML) prema francusko-američko-britanskom (FAB) klasifikacijskom sustavu.
English: Absorption Following subcutaneous administration of a single 75 mg/m dose, azacitidine was rapidly absorbed with peak plasma concentrations of 750 ± 403 ng/mL occurring at 0.5 h after dosing (the first sampling point).
Croatian: Apsorpcija Nakon supkutane primjene jednokratne doze od 75 mg/m2, azacitidin se brzo apsorbirao te se vršna koncentracija azacitidina u plazmi od 750 ± 403 ng/mL postigla za 0,5 h nakon primjene (prva točka uzorkovanja).
English: Azacitidine Celgene 25 mg/mL powder for suspension for injection
Croatian: Azacitidin Celgene 25 mg/mL prašak za suspenziju za injekciju
English: 9/L), baseline bone marrow blasts (≤ 50% & > 50%) and prior history of MDS] there was a trend in OS benefit in favour of azacitidine.
Croatian: 9/L), blastima u koštanoj srži na početku (≤ 50 % i > 50 %) i prethodnom MDS-u u anamnezi].
English: Adult population aged 65 years or older with AML with > 30% marrow blasts The most common serious adverse reactions (≥ 10%) noted from AZA-AML-001 within the azacitidine treatment arm included febrile neutropenia (25.0%), pneumonia (20.3%), and pyrexia (10.6%).
Croatian: Odrasla populacija u dobi od 65 ili više godina s AML-om s > 30 % blasta u koštanoj srži Najčešće ozbiljne nuspojave (≥ 10 %) zabilježene u ispitivanju AZA-AML-001 u skupini liječenoj azacitidinom uključivale su febrilnu neutropeniju (25,0 %), pneumoniju (20,3 %) i pireksiju (10,6 %).
English: Necrotising fasciitis, including fatal cases, have been reported in patients treated with azacitidine.
Croatian: Nekrotizirajući fasciitis, uključujući slučajeve sa smrtnim ishodom, zabilježen je u bolesnika liječenih azacitidinom.
English: Azacitidine treatment improved peripheral blood counts and led to a reduced need for RBC and platelet transfusions.
Croatian: Liječenje azacitidinom poboljšalo je perifernu krvnu sliku i dovelo do smanjenja potrebe za transfuzijama eritrocita i trombocita.
English: Area under the curve and maximum plasma concentration (Cmax) of subcutaneous admiminstration of azacitidine were approximately proportional within the 25 to 100 mg/m dose range.
Croatian: Pri supkutanoj primjeni azacitidina, površina ispod krivulje i maksimalna koncentracija u plazmi (Cmax) bile su približno proporcionalne unutar raspona doza od 25 do 100 mg/m
English: No accumulation occurs after subcutaneous administration of 75 mg/m azacitidine once daily for 7 days.
Croatian: Ne dolazi do nakupljanja azacitidina nakon supkutane primjene 75 mg/m jedanput dnevno tijekom 7 dana.
English: 9/l, and platelets ≥ 75.0 x 10
Croatian: 9/L i trombociti ≥ 75,0 x 10
English: Azacitidine treatment was associated with a median time to death or transformation to AML of 13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months with a stratified log-rank p-value of 0.0025.
Croatian: Liječenje azacitidinom bilo je povezano s medijanom vremena do smrti ili pretvorbe u AML od 13,0 mjeseci naspram 7,6 mjeseci za bolesnike liječene CCR-om, što je poboljšanje od 5,4 mjeseci sa stratificiranom log-rang p-vrijednošću od 0,0025.
English: Azacitidine Celgene 25 mg/mL powder for suspension for injection Azacitidine
Croatian: Azacitidin Celgene 25 mg/mL prašak za suspenziju za injekciju azacitidin
English: CCR consisted of BSC alone (n=45), low-dose cytarabine plus BSC (n=158), or standard intensive chemotherapy with cytarabine and anthracycline plus BSC (n=44).
Croatian: CCR se sastojao od samo BSC-a (n = 45), niske doze citarabina uz BSC (n = 158) ili standardne intenzivne kemoterapije citarabinom i antraciklinom uz BSC (n = 44).
English: ANC ≥ 1.5 x 10
Croatian: ABN ≥ 1,5 x 10
English: When Azacitidine Celgene is reconstituted using water for injections that has not been refrigerated, chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated at 25 °C for 45 minutes and at 2 °C to 8 °C for 8 hours.
Croatian: Kada se Azacitidin Celgene rekonstituira vodom za injekcije koja nije bila rashlađena, kemijska i fizikalna stabilnost rekonstituiranog lijeka u primjeni dokazana je pri 25 °C tijekom 45 minuta i pri 2 °C do 8 °C tijekom 8 sati.
English: Azacitidine Celgene is used in adults who are not able to have a stem cell transplantation to treat:
Croatian: Azacitidin Celgene se primjenjuje kod odraslih kojima se ne mogu transplantirati matične stanice za liječenje:
English: • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
Croatian: • mijelodisplastičnih sindroma (MDS) srednjeg 2 i visokog rizika prema međunarodnom prognostičkom numeričkom sustavu rangiranja (engl.
English: Azacitidine Celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:
Croatian: Azacitidin Celgene je indiciran za liječenje odraslih bolesnika koji nisu zadovoljavali kriterije za transplantaciju hematopoetskih matičnih stanica (THMS), koji boluju od:
English: Patients received the pre-selected regimen if not randomised to azacitidine.
Croatian: Bolesnici su primili unaprijed odabrani režim ako nisu bili randomizirani u skupinu koja prima azacitidina.
English: Azacitidine Celgene works by preventing cancer cells from growing.
Croatian: Azacitidin Celgene djeluje tako što sprječava rast tumorskih stanica.
English: Reconstituted Azacitidine Celgene should be injected subcutaneously (insert the needle at a 45-90° angle) using a 25-gauge needle into the upper arm, thigh or abdomen.
Croatian: Rekonstituirani Azacitidin Celgene treba ubrizgati supkutano (iglu uvesti pod kutom od 45-90°) koristeći se iglom od 25 G u nadlakticu, bedro ili abdomen.
English: Overall response rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) as determined by the IRC was 27.8% in the azacitidine group and 25.1% in the combined CCR group (p = 0.5384).
Croatian: Stopa ukupnog odgovora (potpuna remisija [CR] + potpuna remisija s nepotpunim oporavkom krvne slike [CRi]) kako je utvrdio IRC bila je 27,8 % u skupini liječenoj azacitidinom i 25,1 % kombiniranoj skupini liječenoj CCR-om (p = 0,5384).
English: In the ITT analysis of 358 patients (179 azacitidine and 179 CCR), azacitidine treatment was associated with a median survival of 24.46 months versus 15.02 months for those receiving CCR treatment, a difference of 9.4 months, with a stratified log-rank p-value of 0.0001.
Croatian: U ITT analizi 358 bolesnika (179 s azacitidinom i 179 s CCR-om) liječenje azacitidinom bilo je povezano s medijanom preživljenja od 24,46 mjeseci naspram 15,02 mjeseci kod bolesnika liječenih CCR-om, razlika od 9,4 mjeseci sa stratificiranom log-rang p-vrijednošću od 0,0001.
English: The individual baseline parameters were comparable between the azacitidine and CCR groups.
Croatian: Početni parametri pojedinih bolesnika bili su usporedivi između skupina koje su primale azacitidin i skupina koje su primale CCR.
English: In the ITT analysis of 488 patients (241 azacitidine and 247 CCR), azacitidine treatment was associated with a median survival of 10.4 months versus 6.5 months for those receiving CCR treatment, a difference of 3.8 months, with a stratified log-rank p-value of 0.1009 (two- sided).
Croatian: U ITT analizi 488 bolesnika (od kojih je 241 primao azacitidin, a njih 247 primalo je CCR), liječenje azacitidinom bilo je povezano s medijanom preživljenja od 10,4 mjeseca naspram 6,5 mjeseci za one koji su primali liječenje CCR-om, što je razlika od 3,8 mjeseci, uz stratificiranu log-rang p-vrijednost od 0,1009 (dvostrana).
English: If haematological toxicity is observed following Azacitidine Celgene treatment, the next cycle of the therapy should be delayed until the platelet count and the ANC have recovered.
Croatian: Ako se nakon liječenja Azacitidinom Celgene opazi hematološka toksičnost, sljedeći ciklus liječenja treba odgoditi sve dok se ne oporave vrijednosti trombocita i apsolutnog broja neutrofila.
English: Mannitol (E421)
Croatian: 6.1 Popis pomoćnih tvari Manitol (E421)
English: Reconstituted Azacitidine Celgene should be injected subcutaneously into the upper arm, thigh or abdomen.
Croatian: Rekonstituirani Azacitidin Celgene treba injicirati supkutano u nadlakticu, bedro ili abdomen.
English: Azacitidine Celgene therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.
Croatian: U bolesnika koji razviju nekrotizirajući fasciitis, terapiju Azacitidinom Celgene treba prekinuti i brzo započeti odgovarajuće liječenje.
English: Method of administration Do not filter the suspension after reconstitution.
Croatian: Ne filtrirajte suspenziju nakon rekonstitucije.
English: Azacitidine Celgene is contraindicated in patients with advanced malignant hepatic tumours (see sections 4.3 and 4.4).
Croatian: Azacitidin Celgene je kontraindiciran u bolesnika s uznapredovalim malignim tumorima jetre (vidjeti dijelove 4.3 i 4.4).
English: You will have blood tests before you begin treatment with Azacitidine Celgene and at the start of each period of treatment (called a ‘cycle').
Croatian: Prije početka liječenja Azacitidinom Celgene i prije početka svakog razdoblja liječenja (zvanog „ciklus“) napravit će Vam se krvne pretrage.
English: Azacitidine Celgene contains the active substance ‘azacitidine'.
Croatian: Azacitidin Celgene sadržava djelatnu tvar azacitidin.
English: Following subcutaneous administration of a single 75 mg/m dose, mean exposure values (AUC and Cmax) from subjects with mild, moderate and severe renal impairment were increased by 11-21%, 15-27%, and 41-66%, respectively, compared to normal renal function subjects.
Croatian: U usporedbi s ispitanicima s normalnom funkcijom bubrega, nakon supkutane primjene jednokratne doze od 75 mg/m2, srednje vrijednosti izloženosti (AUC i Cmax) bile su povišene u ispitanika s blagim oštećenjem bubrega za 11-21 %, u onih s umjerenim oštećenjem za 15-27 %, a u bolesnika s teškim oštećenjem bubrega za 41-66 %.
English: 21 days (28 day treatment cycle), for a median of 6 cycles (range: 1 to 28), BSC- only patients for a median of 3 cycles (range: 1 to 20), low-dose cytarabine patients for a median of 4 cycles (range 1 to 25) and standard intensive chemotherapy patients for a median of 2 cycles (range: 1 to 3, induction cycle plus 1 or 2 consolidation cycles).
Croatian: Azacitidin se primjenjivao s.c. u dozi od 75 mg/m na dan tijekom 7 dana, nakon čega je slijedila stanka od uzimanja lijeka od 21 dan (ciklus liječenja od 28 dana), tijekom medijana od 6 ciklusa (raspon: od 1 do 28), bolesnici koji su primali samo BSC tijekom medijana od 3 ciklusa (raspon: od 1 do 20), bolesnici koji su primali nisku dozu citarabina tijekom medijana od 4 ciklusa (raspon: od 1 do 25) i bolesnici koji su primali standardnu intenzivnu kemoterapiju tijekom medijana od 2 ciklusa (raspon: od 1 do 3, uvodni ciklus plus 1 ili 2 konsolidacijska ciklusa).
English: *Recovery = counts ≥ nadir count + (0.5 x [baseline count - nadir count]) Following dose modifications, the cycle duration should return to 28 days.
Croatian: ≥ najniža vrijednost + (0,5 x [početna vrijednost - najniža vrijednost]) Nakon izmjena doze, trajanje ciklusa ponovno treba biti 28 dana.
English: What Azacitidine Celgene contains
Croatian: Što Azacitidin Celgene sadrži
English: If the decrease in WBC or ANC or platelets is greater than 50 % from that prior to treatment, with no improvement in cell line differentiation, the next cycle of Azacitidine Celgene therapy should be delayed until the platelet count and the ANC have recovered.
Croatian: Ako je smanjenje vrijednosti bijelih krvnih stanica ili apsolutnog broja neutrofila ili trombocita veće od 50 % u odnosu na vrijednosti prije početka liječenja, i bez poboljšanja u diferencijaciji stanične linije, sljedeći ciklus liječenja Azacitidinom Celgene treba odgoditi sve dok se vrijednosti trombocita i apsolutnog broja neutrofila ne oporave.
English: Azacitidine treatment led to a reduced need for red blood cell (RBC) and platelet transfusions.
Croatian: Liječenje azacitidinom smanjilo je potrebu za transfuzijom crvenih krvnih stanica i trombocita.
English: Each pack contains one vial of Azacitidine Celgene.
Croatian: Jedno pakiranje sadrži jednu bočicu Azacitidina Celgene.